downsides of bpc 157 BPC-157: Miracle Healing Peptide or Hidden Danger? BPC 157 in Australia: Benefits,

Description

BPC-157 has one human joint study and 35 preclinical studies in orthopedic applications

Clinical Evidence: No IGF-1 Changes Human clinical trials measured serum IGF-1 levels at baseline and throughout treatment with AOD-9604 at various doses

McReynolds MR, et al

Mean age was 42 years, and mean disease duration was 16 years

A 2015 study showed that intra-articular AOD-9604 injections, especially when combined with hyaluronic acid, significantly improved cartilage healing in an animal model of osteoarthritis Future Development Researchers are exploring: Alternative delivery systems (e.g., oral, transdermal) Higher-dose protocols for chronic joint issues Combination peptide therapies for compounded metabolic and regenerative effects As peptide science evolves, AOD-9604 may become a foundational tool in the management of obesity, metabolic dysfunction, and degenerative joint diseases